Literature DB >> 22752931

Late stent thrombosis: the last remaining obstacle in coronary interventional therapy.

Piera Capranzano1, George Dangas.   

Abstract

Drug-eluting stents (DES) represent an outstanding improvement in the interventional cardiology field. DES have markedly decreased stent restenosis and the clinical need for repeat revascularization, without increasing mortality, compared to bare-metal stents (BMS). However, the widespread use of DES has raised concerns regarding the occurrence of late stent thrombosis (ST), beyond the traditional 1-month timeframe in which thrombotic events were found to occur after BMS implantation. While early ST (events occurring within 1 month after stent placement) has been shown to be similar between DES and BMS, late (events occurring after 1 month following stent implantation) and very late (events occurring more than 1 year following stent implantation) ST have emerged as distinct major pitfalls of DES implantation. In this review we describe the current knowledge regarding late and very late ST after DES implantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752931     DOI: 10.1007/s11886-012-0283-9

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  83 in total

1.  Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis.

Authors:  Ehrin J Armstrong; Dmitriy N Feldman; Tracy Y Wang; Lisa A Kaltenbach; Khung-Keong Yeo; S Chiu Wong; John Spertus; Richard E Shaw; Robert M Minutello; Issam Moussa; Kalon K L Ho; Jason H Rogers; Kendrick A Shunk
Journal:  JACC Cardiovasc Interv       Date:  2012-02       Impact factor: 11.195

2.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.

Authors:  Patrick W Serruys; Sigmund Silber; Scot Garg; Robert Jan van Geuns; Gert Richardt; Pawel E Buszman; Henning Kelbaek; Adrianus Johannes van Boven; Sjoerd H Hofma; Axel Linke; Volker Klauss; William Wijns; Carlos Macaya; Philippe Garot; Carlo DiMario; Ganesh Manoharan; Ran Kornowski; Thomas Ischinger; Antonio Bartorelli; Jacintha Ronden; Marco Bressers; Pierre Gobbens; Manuela Negoita; Frank van Leeuwen; Stephan Windecker
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

3.  Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.

Authors:  Duk-Woo Park; Seong-Wook Park; Kyoung-Ha Park; Bong-Ki Lee; Young-Hak Kim; Cheol Whan Lee; Myeong-Ki Hong; Jae-Joong Kim; Seung-Jung Park
Journal:  Am J Cardiol       Date:  2006-06-12       Impact factor: 2.778

4.  Late angiographic stent thrombosis (LAST) events with drug-eluting stents.

Authors:  Andrew T L Ong; Eugène P McFadden; Evelyn Regar; Peter P T de Jaegere; Ron T van Domburg; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2005-06-21       Impact factor: 24.094

5.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

6.  Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization.

Authors:  Lorenz Räber; Peter Jüni; Eveline Nüesch; Bindu Kalesan; Peter Wenaweser; Aris Moschovitis; Ahmed A Khattab; Maryam Bahlo; Mario Togni; Stéphane Cook; Rolf Vogel; Christian Seiler; Bernhard Meier; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2011-05-24       Impact factor: 24.094

7.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.

Authors:  Adnan Kastrati; Julinda Mehilli; Jürgen Pache; Christoph Kaiser; Marco Valgimigli; Henning Kelbaek; Maurizio Menichelli; Manel Sabaté; Maarten J Suttorp; Dietrich Baumgart; Melchior Seyfarth; Matthias E Pfisterer; Albert Schömig
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

8.  Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Ivan Horvath; Matyas Keltai; Jean-Paul R Herrman; Frans Van de Werf; William E Downey; Benjamin M Scirica; Sabina A Murphy; Elliott M Antman
Journal:  Lancet       Date:  2008-04-02       Impact factor: 79.321

9.  Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).

Authors:  José M de la Torre-Hernández; Fernando Alfonso; Felipe Hernández; Jaime Elizaga; Marcelo Sanmartin; Eduardo Pinar; Iñigo Lozano; Jose M Vazquez; Javier Botas; Armando Perez de Prado; Jose M Hernández; Juan Sanchis; Juan M Ruiz Nodar; Alfredo Gomez-Jaume; Mariano Larman; Jose A Diarte; Javier Rodríguez-Collado; Jose R Rumoroso; Jose R Lopez-Minguez; Josepa Mauri
Journal:  J Am Coll Cardiol       Date:  2008-03-11       Impact factor: 24.094

10.  Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.

Authors:  John M Lasala; David A Cox; David Dobies; Kenneth Baran; William B Bachinsky; Edwin W Rogers; Jeffrey A Breall; David H Lewis; Aijun Song; Ruth M Starzyk; Stephen R Mascioli; Keith D Dawkins; Donald S Baim
Journal:  Circ Cardiovasc Interv       Date:  2009-07-22       Impact factor: 6.546

View more
  4 in total

1.  The impact of stent design on the structural mechanics of the crossing Y-stent: an in vitro study.

Authors:  Chang-Young Lee; Seong-Ho Park; Chang-Hyun Kim; Goetz Benndorf
Journal:  Neuroradiology       Date:  2014-05-28       Impact factor: 2.804

2.  3D-printed Bioresorbable Stent Coated with Dipyridamole-Loaded Nanofiber for Restenosis Prevention and Endothelialization.

Authors:  Chengjin Wang; Yang Yang; Jingyuan Ji; Yongcong Fang; Liliang Ouyang; Lei Zhang; Wei Sun
Journal:  Int J Bioprint       Date:  2022-02-19

3.  Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis.

Authors:  Chen He; Yuan-Liang Ma; Chuang-Shi Wang; Lin Jiang; Jia-Hui Zhang; Yi Yao; Xiao-Fang Tang; Bo Xu; Run-Lin Gao; Jin-Qing Yuan
Journal:  Chin Med J (Engl)       Date:  2017-04-20       Impact factor: 2.628

4.  Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study.

Authors:  Jorge A Belardi; Petr Widimský; Franz-Josef Neumann; Laura Mauri; Mariano Albertal
Journal:  J Interv Cardiol       Date:  2013-08-27       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.